Comparison · NCT02725515-c5fb185d
XmAb5871 vs Placebo: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. XmAb5871 vs Placebo: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169. Trial comparisons, record NCT02725515-c5fb185d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02725515-c5fb185d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.58 | 0.442 | 0.706 | wilson | |
| Risk in group 2 | 0.405 | 0.27 | 0.555 | wilson | |
| Risk difference, group 1 minus group 2 | 0.175 | -0.0286 | 0.36 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.43 | 0.927 | 2.22 | log | |
| Odds ratio, group 1 over group 2 | 2.03 | 0.882 | 4.67 | log | |
| Number needed to treat, for one more participant with the outcome on XmAb5871 than on Placebo | 5.71 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | XmAb5871 | XmAb5871 administered by IV infusion for up to a total of 16 infusions | 29 | 50 | OG000 |
| Group 2 | Placebo | Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions | 17 | 42 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169
- Description
- Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 169
- Time frame
- Day 169
- Population
Efficacy Evaluable Population: All patients who:~* Complete study through Day 225 assessments~* Discontinue due to reaching the protocol specified LOI endpoint (and have not missed 2 or more consecutive doses prior to the LOI visit)~* Discontinue due to drug-related adverse event (nonresponder)
Source ClinicalTrials.gov
Trial
- Title
- A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
- NCT number
- NCT02725515
- Phases
- PHASE2
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- XmAb5871, Placebo to match XmAb5871
- Lead sponsor
- Xencor, Inc.
- Results first posted
- 2019-08-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02725515?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02725515-c5fb185d